| Drug NDC: | 55714-4841 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. | |
| Proprietary Name: | Hbp |
| Also known as the trade name. It is the name of the product chosen by the labeler. | |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. | |
| Non Proprietary Name: | Ruta Graveolens, Valeriana Officinalis, Adrenalinum, Arsenicum Iodatum, Aurum Metallicum, Baryta Carbonica, Bryonia, Cactus Grandiflorus, Chelidonium Majus, Cinchona Officinalis, Crotalus Horridus, Digitalis Purpurea, Glonoinum, Kali Carbonicum, Kali Iodatum, Lachesis Mutus, Naja Tripudians, Nux Vomica, Veratrum Album, Vipera Berus, Viscum Album, Elaps Corallinus. |
| Also known as the generic name, this is usually the active ingredient(s) of the product. | |
| Labeler Name: | Newton Laboratories, Inc. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. | |
| Dosage Form: | Liquid |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. | |
| Substance Name: | ARSENIC TRIIODIDE - 15 [hp_X]/mL BARIUM CARBONATE - 15 [hp_X]/mL BRYONIA ALBA ROOT - 15 [hp_X]/mL CHELIDONIUM MAJUS - 15 [hp_X]/mL CINCHONA OFFICINALIS BARK - 15 [hp_X]/mL CROTALUS HORRIDUS HORRIDUS VENOM - 15 [hp_X]/mL DIGITALIS - 15 [hp_X]/mL EPINEPHRINE - 15 [hp_X]/mL GOLD - 15 [hp_X]/mL LACHESIS MUTA VENOM - 15 [hp_X]/mL Load more... MICRURUS CORALLINUS VENOM - 30 [hp_X]/mL NAJA NAJA VENOM - 15 [hp_X]/mL NITROGLYCERIN - 15 [hp_X]/mL POTASSIUM CARBONATE - 15 [hp_X]/mL POTASSIUM IODIDE - 15 [hp_X]/mL RUTA GRAVEOLENS FLOWERING TOP - 6 [hp_X]/mL SELENICEREUS GRANDIFLORUS STEM - 15 [hp_X]/mL STRYCHNOS NUX-VOMICA SEED - 15 [hp_X]/mL VALERIAN - 6 [hp_X]/mL VERATRUM ALBUM ROOT - 15 [hp_X]/mL VIPERA BERUS VENOM - 15 [hp_X]/mL VISCUM ALBUM FRUITING TOP - 15 [hp_X]/mL |
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. | |
| Route Details: | ORAL |
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Start Date: | 18 May, 2020 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. | |
| Marketing End Date: | 24 Jun, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. | |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. | |
| Manufacturer Name: | Newton Laboratories, Inc. |
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. | |
| Original Packager: | Yes |
| Whether or not the drug has been repackaged for distribution. | |
| NUI: | N0000000209 N0000000245 N0000175552 N0000175555 N0000175570 M0003647 N0000185508 N0000175629 N0000184306 M0000728 N0000175415 M0014874 N0000009909 N0000185375 N0000185001 M0016962 M0516536 |
| Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT). | |
| UNII: | 3029988O2T 6P669D8HQ8 T7J046YI2B 7E889U5RNN S003A158SB YHA2XLJ956 F1T8QT9U8B YKH834O4BH 79Y1949PYO VSW71SS07I Load more... V0S6H36980 ZZ4AG7L7VM G59M7S0WS3 BQN1B9B9HA 1C4QK22F9J N94C2U587S 7114SV0MYK 269XH13919 JWF5YAW3QW QNS6W5US1Z 0ORO6NCA4M BK9092J5MP |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. | |
| Pharmacologic Class MOA: | Adrenergic alpha-Agonists [MoA] Adrenergic beta-Agonists [MoA] |
| Mechanism of action of the drug—molecular, subcellular, or cellular functional activity—of the drug’s established pharmacologic class. Takes the form of the mechanism of action, followed by `[MoA]` (such as `Calcium Channel Antagonists [MoA]` or `Tumor Necrosis Factor Receptor Blocking Activity [MoA]`. | |
| Pharmacologic Class EPC: | alpha-Adrenergic Agonist [EPC] beta-Adrenergic Agonist [EPC] Catecholamine [EPC] Standardized Chemical Allergen [EPC] Nitrate Vasodilator [EPC] Non-Standardized Plant Allergenic Extract [EPC] |
| Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`. | |
| Pharmacologic Class PE: | Increased Histamine Release [PE] Cell-mediated Immunity [PE] Vasodilation [PE] Increased IgG Production [PE] |
| Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`. | |
| Pharmacologic Class CS: | Catecholamines [CS] Allergens [CS] Nitrates [CS] Plant Proteins [CS] Seed Storage Proteins [CS] |
| Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient]. | |
| Pharmacologic Class: | Adrenergic alpha-Agonists [MoA] Adrenergic beta-Agonists [MoA] Allergens [CS] Catecholamine [EPC] Catecholamines [CS] Cell-mediated Immunity [PE] Increased Histamine Release [PE] Increased IgG Production [PE] Nitrate Vasodilator [EPC] Nitrates [CS] Non-Standardized Plant Allergenic Extract [EPC] Plant Proteins [CS] Seed Storage Proteins [CS] Standardized Chemical Allergen [EPC] Vasodilation [PE] alpha-Adrenergic Agonist [EPC] beta-Adrenergic Agonist [EPC] |
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. | |
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|---|---|---|---|
| 55714-4841-1 | 30 mL in 1 BOTTLE, GLASS (55714-4841-1) | 18 May, 2020 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. | ||||
* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.